Skip Navigation


JAC Advance Access originally published online on June 17, 2009
Journal of Antimicrobial Chemotherapy 2009 64(2):218-222; doi:10.1093/jac/dkp205
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
64/2/218    most recent
dkp205v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Taylor, S.
Right arrow Articles by Smit, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taylor, S.
Right arrow Articles by Smit, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading articles

Using HIV resistance tests in clinical practice

Stephen Taylor1,2,*, Ashini Jayasuriya1 and Erasmus Smit1,3

1 Directorate of Sexual Medicine and HIV, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UK 2 Division of Immunity and Infection, University of Birmingham, Birmingham, UK 3 HPA Birmingham, Public Health Laboratory, Birmingham Heartlands Hospital, Birmingham, UK

* Corresponding author. Tel: +44-121-424-3365; Fax: +44-121-424-3300; E-mail: steve.taylor{at}heartofengland.nhs.uk

Genotypic resistance testing is now a standard of care in HIV management. Although there are clear, published guidelines to recommend the appropriate use of these tests, clinicians and scientists still struggle to determine the optimal use of resistance tests given the finite budgets and time constraints under which they work. In this article we discuss some ‘real-life’ clinical situations and aim to provide a useful insight into when and where genotypic resistance testing can be optimally applied in the management of HIV-positive adults.

Keywords: human immunodeficiency virus , genotype , genotypic resistance testing


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.